Non-coding RNAs in radiotherapy resistance: Roles and therapeutic implications in gastrointestinal cancer - 28/03/23

Doi : 10.1016/j.biopha.2023.114485

Kaiyue Xu ^a,^b,^{^{1
Kaiyue Xu, Huimin Guo, and Anliang Xia contributed equally to this work.}}, Huimin Guo ^c,^{^{1
Kaiyue Xu, Huimin Guo, and Anliang Xia contributed equally to this work.}}, Anliang Xia ^a,^{^{1
Kaiyue Xu, Huimin Guo, and Anliang Xia contributed equally to this work.}}, Zhangding Wang ^c,^⁎ , Shouyu Wang ^a,^d,^⁎ , Qiang Wang ^e,^f,^⁎
^a Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210000, China
^b Department of Radiation Oncology, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou 215000, China
^c Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210000, China
^d Jiangsu Key Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing 210093, China
^e Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China
^f Medical Transformation Research Institute, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China

^⁎Corresponding author.^⁎⁎Corresponding author at: Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210000, China.Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical SchoolNanjing210000China.^⁎⁎⁎Corresponding author at: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical UniversityHefei230000China.

Abstract

Radiotherapy has become an indispensable and conventional means for patients with advanced solid tumors including gastrointestinal cancer. However, innate or acquired radiotherapy resistance remains a significant challenge and greatly limits the therapeutic effect, which results in cancer relapse and poor prognosis. Therefore, it is an urgent need to identify novel biomarkers and therapeutic targets for clarify the biological characteristics and mechanism of radiotherapy resistance. Recently, lots of studies have revealed that non-coding RNAs (ncRNAs) are the potential indicators and regulators of radiotherapy resistance via the mediation of various targets/pathways in different cancers. These findings may serve as a potential therapeutic strategy to overcome radiotherapy resistance. In this review, we will shed light on the recent findings regarding the functions and regulatory mechanisms of ncRNAs following radiotherapy, and comprehensively discuss their potential as biomarkers and therapeutic targets in radiotherapy resistance of gastrointestinal cancer.

Le texte complet de cet article est disponible en PDF.

Highlights

●	Nc-RNAs are involved in radiotherapy resistance of gastrointestinal cancer.
●	Nc-RNAs regulates radiosensitivity by targeting various targets/pathways in tumour cell and tumor microenvironment.
●	Elucidating the potential of nc-RNAs as biomarkers and targets for gastrointestinal cancer radiosensitivity.

Le texte complet de cet article est disponible en PDF.

Abbreviations : EC, ESCC, GC, PC, HCC, CRC, ncRNAs, SRT, 3DCRT, PRT, SSBs, DSBs, ROS, RNS, miRNAs, lncRNAs, circRNAs, CSCs, mRNA, UV, DDR, MMR, BER, NER, HR, NHEJ, Cyt c, DR, TNFR1, TRAIL-Rs, FADD, ATGs, Rab7, FYCO1, EMT, ATG, ATG3, ATG5, ATG7, ATG9, ATG8, ATG12, ATG 16, ATG16L1, ATM, ATR, AIFM3, AKTPKB, ARID4B, APAF1, BTG2, BTG3, BCL-2, BCL2L2, Bax, Bak, BEX1, BRCA1, c-Met, CAFs, CCAR1, CKS1, β-Catenin CTNNB1, CDC2, CDC25A, CHK2, CDK, CKI, CDK4, CHD5, CARM1, Dox, DCLK1, DYRK1A, DUSP10, DNMT3b, ECM, EZH2, EEPD1, EGFR, ERBB4, ERK, Fas, FANCD2, FOXO1, FOXO3a, FOXM1, FOXP1, FOXA1, FBXW7, GPX8, GABARAP, GSDME, GPC3, GSK-3β, H2AX, HDAC2, HIF-1α, JAK, MDSCs, MSH2, IGF1R, IL6R, IGF2BP1, IGF2, LIG4, LC3-Ⅱ, LAT2, JNK, KLF10, MET, MSI1, mTOR, MUC1, MIF, MAPK1, MAP3K3, MAP3K10 MLK2, MRN complex, MMP2, MMP9, MEK, NBS1, OLR1, PAK3, PE, p70S6K1 RPS6KB1, PDK1, PI3K, PTEN, PDGFβ, PDGFRβ, PRRX1, PSEN1, PARP9, PEX5, pRb, p57kip2, PBK, RECK, RHCG, RPA3, Rb gene, sEVs, SMC-1, SPIN1, SIRT1, SP1, SAPK, SETD1A, SETDB1, SOX4, SOX9, STK40, STAT, SMAD2, SMAD4, SNAI1, SLUG SNAI2, TGFB3, Tip60, TME, TAMs, TCF4, TOB1, TWIST, TP53RK, ULK1, UVRAG, WNT1, WISP1, WIF-1, XIAP, YAP, YBX1, YY1, ZEB, ZEB1, ZNF587, Zo-1 TGP1, PDO, PDX

Keywords : Gastrointestinal cancer, Radiotherapy resistance, NcRNAs, Biomarkers, Therapeutic targets

Plan

Introduction

ncRNAs-mediated radio-resistance in gastrointestinal cancer

ncRNAs in DNA damage repair

ncRNAs-medicated cell cycle arrest

ncRNAs-medicated apoptosis

ncRNAs-medicated autophagy

CRediT authorship contribution statement

Export

Vol 161

Article 114485- mai 2023 Retour au numéro

Article précédent

Quercetin activates the Sestrin2/AMPK/SIRT1 axis to improve amyotrophic lateral sclerosis
Tian Jin, Yong Zhang, Benson O.A. Botchway, Min Huang, Qicheng Lu, Xuehong Liu

| Article suivant

Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives
Hamid Aria, Marzieh Rezaei

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Non-coding RNAs in radiotherapy resistance: Roles and therapeutic implications in gastrointestinal cancer - 28/03/23

Abstract

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL